1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Eccrine Porocarcinoma: new trials by email Literature Review of Eccrine Porocarcinoma trials Research Report on Eccrine Porocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
Adenocarcinoma, Papillary (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Microcystic adnexal carcinoma (1) · Muir-Torre Syndrome (1) · Mycosis Fungoides (1) · Paget Disease, Extramammary (1) · Sezary Syndrome (1)
Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Virus Infections (1) · Genetic Diseases, Inborn (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1)
Biopsy (1) · Nivolumab (1) · Specimen Handling (1) · talimogene laherparepvec (1)
National Cancer Institute (NCI) (1)
United States (1)
UM1CA186709 (1), UM1CA186716 (1)